Genetic Architecture of N-Terminal Pro-B-Type Natriuretic Peptide in a Multiancestry Study Population

Read full text
Authors: Naman S. Shetty, Akhil Pampana, Mokshad P. Gaonkar, Amrita Nayak, Harshvir Singh Bal, Nirav Patel, Nehal Vekariya, J. Gustav Smith, Alanna C. Morrison, Bing Yu, Bruce M. Psaty, Eric Boerwinkle
+13 more James S. Floyd, Jerome I. Rotter, Kent D. Taylor, Leslie A. Lange, Marguerite R. Irvin, Mary Cushman, Stephen S. Rich, Ramachandran Srini Vasan, Thomas J. Wang, Xiuqing Guo, Peng Li, Garima Arora, Pankaj Kumar Arora
Cited by: 0
References: 120

Abstract

BACKGROUND: NPs (natriuretic peptides) are bioactive hormones crucial for regulating blood pressure, glucose homeostasis, and lipid metabolism. Despite the high heritability of circulating NP levels, the genetic determinants of NP regulation, particularly across ancestries and sexes, remain poorly understood. The objective of the current study was to identify genetic variants associated with NT-proBNP (N-terminal pro-B-type NP) levels in a multiancestry study population. METHODS: Whole genome sequencing and array-based data from 81 213 individuals without heart failure were analyzed from the Trans-Omics for Precision Medicine cohorts, UK Biobank, All of Us Research Program, and REGARDS (Reasons for Geographic and Racial Differences in Stroke) study to identify common, rare, and structural variants associated with NT-proBNP levels. The main outcome of the study was rank-based inverse normal and standardized NT-proBNP levels. Genetic associations with NT-proBNP were examined, followed by gene prioritization, transcriptome-wide association studies, colocalization, and rare variant analyses. RESULTS: (4q24) were identified through gene prioritization, with prior animal models supporting their therapeutic relevance. Rare variant analysis identified 6 masks with significant associations, specifically non-coding masks, suggesting regulatory modulation of NT-proBNP. CONCLUSIONS: This study identifies novel common, rare, and structural variants associated with NT-proBNP levels, highlighting the contribution of both coding and regulatory non-coding variation. These findings advance our understanding of the genetic architecture of NT-proBNP and may inform future cardiometabolic therapeutic strategies.

Fields of Study & Subjects

Genetic Associations and Epidemiology Heart Failure Treatment and Management Genetics and Physical Performance

Publication details

Journal / source
Circulation Genomic and Precision Medicine
Volume
19
Issue
1
Pages
e005130–e005130
Publication date
28 January 2026
Language
EN